Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;9(2):45-53.
doi: 10.1177/1759720X16673786. Epub 2017 Jan 20.

Apremilast in the treatment of psoriatic arthritis: a perspective review

Michael Reed  1 , David Crosbie  2
Affiliations
Review

Apremilast in the treatment of psoriatic arthritis: a perspective review

Michael Reed et al. Ther Adv Musculoskelet Dis. 2017 Feb.

Abstract

Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease. Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy. We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA.

Keywords: PALACE; apremilast; psoriasis; psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: DC has received speaker fees from Celgene within the UK to a total of less tan £3000. MR has no conflicts of interest in preparing this article.

References

    1. Adebajo A., Gladmann D., Kavanaugh A., Mease P., Gomez-Reino J., Hall S., et al. (2015) Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase iii, randomized, controlled trial and open-label extension (PALACE 1). Rheumatol 54(Suppl. 1): i133.
    1. Alibert J. (1818) Precis Theorique Et Pratique Sur Les Maladies de La Peau. Paris: Caille et Ravier, p; 21.
    1. Betts K., Griffith J., Friedman A., Zhou Z., Signorovitch J., Ganguli A. (2016) An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis. Curr Med Res Opin 32: 721–729. - PubMed
    1. Caso F., Costa L., Atteno M., Del Puente A., Cantarini L., Lubrano E., et al. (2014) Simple clinical indicators for early psoriatic arthritis detection. Springerplus 3: 759. - PMC - PubMed
    1. Caso F., Del Puente A., Peluso R., Caso P., Girolimetto N., Del Puente A., et al. (2016) Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs 21: 69–79. - PubMed

LinkOut - more resources